Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial-Reference-Cited by-同舟云学术

Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial

Published:2005-02 Issue:9460 Volume:365 Page:657-662
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Bocchia M,Gentili S,Abruzzese E,Fanelli A,Iuliano F,Tabilio A,Amabile M,Forconi F,Gozzetti A,Raspadori D,Amadori S,Lauria F

Publisher

Elsevier BV

Subject

General Medicine

Reference28 articles.

1. Chronic myeloid leukemia;Sawyers;N Engl J Med,1999

2. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products;Lugo;Science,1990

3. Induction of chronic myelogenous leukemia in mice by the p210bcr/abl gene of the Philadelphia chromosome;Daley;Science,1990

4. Effect of a selective inhibitor of the Abl tyrosine kinase on the growth of bcr-abl positive cells;Druker;Nat Med,1996

5. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia;Kantarjian;N Engl J Med,2002

Cited by 73 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Peptides for microbe-induced cancers: latest therapeutic strategies and their advanced technologies;Cancer and Metastasis Reviews;2024-07-15

2. Key principles of drug therapy in patients with chronic myeloid leukemia;FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology;2023-07-20

3. Regulation of hematopoietic and leukemia stem cells by regulatory T cells;Frontiers in Immunology;2022-11-02

4. Harnessing gene fusion-derived neoantigens for ‘cold’ breast and prostate tumor immunotherapy;Immunotherapy;2022-10

5. A randomized, phase II trial of adjuvant immunotherapy with durable TKI-free survival in patients with chronic phase CML;Leukemia Research;2021-12